Abstract
Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.
Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.
Graphical Abstract
Current Signal Transduction Therapy
Title:Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Volume: 9 Issue: 2
Author(s): Junben Wu, Muhammad Shahbaz, Shujing Wang, Bengang Gong, Benjia Liang, Ruliang Fang, Bo Qiu, Min Jiang, Yang Li and Jun Niu
Affiliation:
Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.
Abstract: Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.
Export Options
About this article
Cite this article as:
Wu Junben, Shahbaz Muhammad, Wang Shujing, Gong Bengang, Liang Benjia, Fang Ruliang, Qiu Bo, Jiang Min, Li Yang and Niu Jun, Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362409666141201202706
DOI https://dx.doi.org/10.2174/1574362409666141201202706 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry Multi Fractal Process of Powder Particle Breakage and Aggregation
Current Nanoscience Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry